Navigation Links
Simvastatin Leads Pfizer's Lipitor in Second-Line Patient Share for the Treatment of Dyslipidemia
Date:5/13/2008

Results from the ENHANCE Trial Impacting Physician Prescribing Patterns,

According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that simvastatin (Merck's Zocor, generics) leads Pfizer's Lipitor in second-line patient share -- 22.9 percent versus 14.7 percent. Most patients progressing to simvastatin do so after switching from Lipitor. Surveyed primary care physicians and cardiologists cite simvastatin's better reimbursement and formulary status as the primary reason to prescribe simvastatin instead of Lipitor. Nevertheless, despite the availability of generic statins, more than 75 percent of Lipitor's prescriptions stem from first-line therapy.

The report entitled Treatment Algorithms in Dyslipidemia also finds that, prior to the release of the ENHANCE trial results, Merck/Schering-Plough's Vytorin and AstraZeneca's Crestor also gained significant second-line patient shares-13.1 percent and 10.9 percent, respectively. These gains reflect physicians' efforts to boost efficacy in patients whose initial low-density lipoprotein (LDL) lowering treatment had been less than optimal; surveyed physicians perceive these agents to offer the best LDL-reducing ability. However, 47 percent of surveyed primary care physicians and 49 percent of surveyed cardiologists have changed their prescribing of Merck/Schering- Plough's Zetia and Vytorin because of data from the ENHANCE trial, which showed that the addition of Zetia to simvastatin treatment did not significantly change carotid artery thickness. The majority of surveyed physicians now prescribe Vytorin and Zetia in fewer new patients, with a smaller percentage of physicians switching patients off of these drugs.

"Cardiologists we surveyed expect to decrease their first- and second-line prescriptions for Vytorin between 2008 and 2010,
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Abbotts Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
2. Nursing professor leads the way for telepsychiatry by nurses to treat postpartum depression
3. Prisoner HIV program leads to continuum of medical care after release
4. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
5. Minimally invasive pancreas surgery leads to fewer complications, study finds
6. UQ leads the way on complementary medicine research
7. Prostate cancer screening program leads to bigger fall in death rates than surrounding areas
8. When positive thinking leads to financial irresponsibility like compulsive gambling
9. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy
10. Eli Manning Leads March for Babies in Manhattan
11. MRI before surgery leads to better-adapted treatment for breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... at the University of California, San Diego School of ... in chili peppers produces chronic activation of a ... a reaction that ultimately reduces the risk of colorectal ... 1, 2014 issue of The Journal of Clinical ... TRPV1, was originally discovered in sensory neurons, where it ...
(Date:8/1/2014)... brain plays a central role in regulating appetite and ... in the brain,s control of food intake and body ... process has been unclear. A new study ... that PPARγ activity in a type of neuron known ... response to high-fat diet. Sabrina Diano and colleagues ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 (HealthDay News) ... have significantly less endurance than those who weigh less, a new ... were obese, half were of normal weight -- people who were ... Obesity also was associated with less strength, increased discomfort and ... to 65 years of age -- neither improved nor reduced a ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... study, researchers at University Hospitals Rainbow Babies & Children,s ... at greater risk for death on a commercial airline ... worldwide between January 2010 and June 2013 and found ... age of 2. , The study was conducted ... of an in-flight pediatric fatality onboard commercial airline flights ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:New research characterizes in-flight pediatric deaths 2
... Mayo is the first organization approved for three specialties ... The American Board of Family Medicine (ABFM), ... American Board of Pediatrics (ABP)—the nation,s three largest physician certifying ... Sponsor of Maintenance of Certification (MOC) activities. Mayo Clinic,s rigorous attention ...
... , SAN DIEGO , Jan. 27 ... that the Company will report its fourth quarter and year-end 2009 ... 2010.  Neurocrine will then host a  live conference call and webcast ... afternoon, February 3, 2010 at 5:00 p.m. Eastern ...
... a leading source of adult stem cells, which are ... the cells is an arduous and often painful process. ... as adipose tissue, may be a promising new source ... and progenitor cells (HSPCs), according to a study ...
... United States has an inefficient and expensive health care system, ... care system detailed in a new study in the ... No. 2). According to the authors of ... Health Care System" from Ben-Gurion University of the Negev (BGU) ...
... of Medicine has been awarded six Department of ... grants for innovative medical research. The grants, totaling ... field of breast cancer. Case Western ... awards and three Idea Awards. The three postdoctoral ...
... few anti-spasticity medications used for children with cerebral palsy ... according to a new review of scientific literature headed ... by a national panel of interdisciplinary experts nationwide. ... release a new practice guideline on effective treatments. Dr. ...
Cached Medicine News:Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 2Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 3Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 4Health News:Mayo Clinic Recognized by Three Certifying Boards for Quality Improvement Activities 5Health News:Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2009 Financial Results 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 2Health News:Fat tissue may be a source of valuable blood stem cells, study says 3Health News:Integrating private insurance with public health would improve US health care -- study 2Health News:Case Western Reserve receives $2.8 million to further breast cancer research 2Health News:Anti-spasticity medications need further research 2
(Date:7/31/2014)... Pa. , July 31, 2014   Auxilium ... fully integrated specialty biopharmaceutical company, today announced that the ... 2014 on Thursday, August 7, 2014 before the opening ... conduct a conference call that day at 8:30 a.m. ... quarter of 2014. The presentation slides to be used ...
(Date:7/31/2014)... Fla. , July 31, 2014 Rock ... today that it has initiated the development of its ... ; and that it has selected Quotient Clinical, The ... Kingdom (UK) to run its early development ... Clinical Trial Application (CTA) by the end of the ...
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 13 Eli Lilly and Company (NYSE: LLY ... vice president, science and technology, and president, Lilly Research ... Lilly has also announced that Jan M. Lundberg, Ph.D., ... AstraZeneca, is to become his successor. Paul is committed ...
... Millar Instruments, Inc. developer and manufacturer of Mikro-Tip® ... Harvard Apparatus, manufacturer of specialty life science equipment, ... DiGiusto, President of Harvard Apparatus states, "We are ... Instruments to provide comprehensive solutions for physiology research. ...
Cached Medicine Technology:Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 2Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Discovery Research, AstraZeneca, Named his Successor 3Millar Instruments and Harvard Apparatus Improve Ability to Provide Customers With Total Physiology Solutions Through Joint Distribution Agreement 2
Stainless steel bone clamp....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
The AV Plus DX pacing lead is designed for use with the St. Jude Medical Affinity VDR pulse generator. This single-lead pacing system provides reliable pacing therapy with the added benefits of AV sy...
Medicine Products: